| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | TCD; GGTA; REP-1; DXS540; HSD-32 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CHM |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CHM抗体的3篇示例文献(内容为模拟虚构，仅供参考)：
1. **文献名称**：*Development of a Novel Monoclonal CHM Antibody for Ovarian Cancer Diagnosis*
**作者**：Zhang L, et al.
**摘要**：研究团队开发了一种针对CHM抗原的单克隆抗体，通过免疫组化验证其在卵巢癌组织中的高特异性表达，表明其可作为潜在的生物标志物用于临床诊断。
2. **文献名称**：*CHM Autoantibodies in Recurrent Miscarriage: Clinical Significance and Mechanisms*
**作者**：Wang Y, et al.
**摘要**：本文探讨了抗CHM抗体与复发性流产的关联，发现患者血清中CHM抗体水平升高可能通过干扰胎盘血管生成导致妊娠失败，提示其作为免疫治疗靶点的潜力。
3. **文献名称**：*Structural Characterization of CHM Antigen-Antibody Interaction by Cryo-EM*
**作者**：Smith J, et al.
**摘要**：利用冷冻电镜技术解析了CHM抗原与其单克隆抗体的复合物结构，揭示了抗体结合表位的关键氨基酸残基，为优化抗体药物设计提供了理论依据。
注：以上文献及内容为示例，实际研究中请通过学术数据库(如PubMed、Google Scholar)检索真实发表的文献。
Chimeric antibodies (CHM antibodies) are engineered molecules that combine genetic material from different species, typically human and murine (mouse), to enhance therapeutic efficacy and reduce immunogenicity. Developed through recombinant DNA technology, these antibodies merge the antigen-binding regions (variable regions) of a mouse monoclonal antibody with the constant regions of a human antibody. This design aims to retain the specificity and affinity of murine antibodies while minimizing adverse immune reactions often triggered by fully foreign proteins.
The concept emerged in the 1980s as scientists sought to overcome limitations of early murine-derived monoclonal antibodies, which were effective in targeting antigens but frequently caused human anti-mouse antibody (HAMA) responses. CHM antibodies became a pivotal innovation in immunotherapy, particularly for cancer and autoimmune diseases. For example, drugs like rituximab (anti-CD20) and infliximab (anti-TNF-α) utilize this chimeric structure to achieve targeted action with improved tolerability.
CHM antibodies laid the groundwork for subsequent generations of engineered antibodies, including humanized and fully human antibodies. Their development marked a milestone in biopharmaceuticals, enabling safer, long-term treatments and expanding the scope of precision medicine. Today, they remain widely used in clinical settings, underscoring their enduring impact on therapeutic antibody design.
×
